WM — Jul 28, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001104659-25-071187
Showing in the filing
Anticipated run-rate synergies (including cross-selling opportunities)
“$300 million of operating EBITDA”
Period
FY2027
Measure
Company-defined measure
Source
Prose
All guidance in this release · 22
WM Healthcare Solutions targeted synergies for FY2025
“$80 to $100 million”
Operating EBITDA opportunities from cross-se…
“$50 million”
Anticipated run-rate synergies (including cr… for FY2027
“$300 million of operating EBITDA”
Run-rate synergies for FY2027
“$300 million of operating EBITDA”
Adjusted operating EBITDA midpoint for FY2025
“$7.550 billion”
Adjusted operating EBITDA for FY2025
“$7.475 and $7.625 billion”
Free cash flow for FY2025
“between $2.8 and $2.9 billion”
Total Company revenue for FY2025
“between $25.275 and $25.475 billion”
Adjusted operating EBITDA margin for FY2025
“between 29.6% and 29.9%”
Blended average price received for single st… for FY2025
“about $80 per ton”
Net cash provided by operating activities (S… for FY2025
“$5,860”
Net cash provided by operating activities (S… for FY2025
“$6,025”
Capital expenditures to support the business… for FY2025
“(2,575)”
Capital expenditures to support the business… for FY2025
“(2,625)”
Proceeds from divestitures of businesses and… for FY2025
“115”
Proceeds from divestitures of businesses and… for FY2025
“150”
Free cash flow without sustainability growth… for FY2025
“$3,400”
Free cash flow without sustainability growth… for FY2025
“$3,550”
Capital expenditures - sustainability growth… for FY2025
“(600)”
Capital expenditures - sustainability growth… for FY2025
“(650)”
Free cash flow (Scenario 1) for FY2025
“$2,800”
Free cash flow (Scenario 2) for FY2025
“$2,900”
Exhibit 99.1 · the passage around this item
… earlier in the release
· Integration
of WM Healthcare Solutions continues to advance, and as announced during the June Investor
Day, the Company has identified $50 million of operating EBITDA opportunities from cross-selling
solid waste and medical waste solutions to existing customers, with $11 million of annualized
operating EBITDA already secured. Including the cross-selling opportunities, anticipated
run-rate synergies are expected to total $300 million of operating EBITDA by 2027.
2025 Outlook
With two quarters of
the year complete, the Company is confident in its ability to deliver upon its full-year outlook for adjusted operating EBITDA and is
positioned to deliver free cash flow in excess of its initial target.
· The
Company delivered adjusted operating EBITDA in the first six months of the year in line with
its expectations and initial guidance. The Company is affirming its adjusted operating EBITDA
guidance midpoint of $7.550 billion and narrowing its range slightly to $7.475 and $7.625
billion. (a)
· Free
cash flow is now projected to be between $2.8 and $2.9 billion, an increase of $125
million from the Company’s initial guidance. (a) The increase in the
free cash flow outlook is driven by recently enacted tax policy that restores bonus depreciation
to 100%.
· Total
Company revenue is now expected to be between $25.275 and $25.475 billion. The
decrease from prior expectations is primarily related to the recent decline in recycled commodity
prices which has an outsized impact on the Company’s low-margin recycling brokerage
business, as well as the impacts of a decline in
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.